Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2015-06-26

Clinical Trial Update: Intraarticular Injection of Infliximab [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial evaluating intraarticular infliximab for arthritis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Infliximab (infliximab)

Snippet

Sponsor: HaEmek Medical Center, Israel | Conditions: Arthritis | Phase 2, Phase 3 | Status: WITHDRAWN